Heredity and Alzheimer's disease: Basic findings and clinical implications

Current Opinion in Psychiatry

Volumn 11, Issue 4, 1998, Pages 417-423

  Scott, William K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MEDICAL ETHICS; MULTIFACTORIAL INHERITANCE; REVIEW;

EID: 0031829565     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199807000-00010     Document Type: Review

References (101)

1. Max W. The economic impact of Alzheimer's disease. Neurology 1993; 43(suppl 4):S6-S10.
2. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer beta-amyloid. Biochem Biophys Res Commun 1993; 192:359-365.
3. Small GW. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273:942-947.
4. Gatz M, Pedersen NL. Use of twin samples to estimate the heritability of Alzheimer's disease: a methodological note. Alzheimer's Res 1996; 2:229-232.
5. Risch N. Linkage strategies for genetically complex traits I. Multilocus models. Am J Hum Genet 1990; 46:222-228.
6. Mickel SF, Broste SK, Hiner BC. Lack of overlap in genetic risks for Alzheimer's disease and Parkinson's disease. Neurology 1997; 48:942-949.
7. Breitner JC, Silverman JM, Mohs RC, Davis KL. Familial aggregation in Alzheimer's disease: comparison of risk among first degree relatives of early- and late-onset cases, and among male and female relatives in a successive generation. Neurology 1988; 38:207-212.
8. Sadovnick AD, Irwin ME, Baird PA, Beattle BL. Genetic studies on an Alzheimer clinic population. Genet Epidemiol 1989; 6:663-643.
9. Hirst C, Sadovnick AD, Yee IML. Familial risks for Alzheimer disease: data from an Alzheimer clinic population. Genet Epidemiol 1994; 11:365-374.
10. Pericak-Vance MA, Haines JL. Genetic susceptibility to Alzheimer disease. Trends Genet 1995; 11:504-508.
11. Lendon CL, Ashall F, Goate AM. Exploring the etiology of Alzheimer disease using molecular genetics. JAMA 1997; 277:825-831. This recent review article focuses on the molecular genetics of Alzheimer's disease, including the structure and function of the presenilins.
12. Levy-Lahad E, Bird TD. Genetic factors in Alzheimer's disease: a review of recent advances. Ann Neurol 1996; 40:829-840.
13. Goate AM, Chartier-Harlin MC, Mullan MC, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor proteingene with familial Alzheimer's disease. Nature 1991; 349:704-706.
14. Sherrington R, Rogaev E, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a novel gene bearing mis-sense mutations in early familial Alzheimer's disease. Nature 1995; 375:754-760.
15. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269:973-977.
16. Rogaev E, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang G, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376:775-778.
17. Bird TD, Levy-Lahad E, Poorkaj P, Sharma V, Nemens E, Lahad A, et al. Wide range in age of onset for chromosome 1-related familial Alzheimer's disease. Ann Neurol 1996; 40:932-936.
18. Sherrington R, Froelich S, Sorbi S, Campion D, Chi H, Rogaeva EA, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5:985-988.
19. Kwok JBJ, Taddei K, Hallupp M, Fisher C, Brooks WS, Broe G, et al. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. NeuroReport 1997; 8:1537-1542.
20. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923.
21. Saunders AM, Strittmatter WJ, Breitner JC, Schmechel D, St George-Hyslop PH, Pericak-Vance MA, et al. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472.
22. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance MA, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90:1977-1981.
23. Roses AD, Pericak-Vance MA. Alzheimer's disease and other dementias. In: Emery and Rimoin's principles and practice of medical genetics. Connon JM (editor). 3rd ed. New York: Churchill Livingston Publishing Co.; 1997. This review, by investigators who discovered the ApoE effect in late-onset Alzheimer's disease, discusses the worldwide confirmation of the effect of the ApoE-4 allele.
24. Roses AD, Devlin B, Conneally PM, Small GW, Saunders AM, Pritchard M, et al. Measuring the genetic contribution of APOE in late-onset Alzheimer disease (AD) (abstract). Am J Hum Genet 1995; 57:A202.
25. Blacker D, Haines JL, Rodes L, Terwedow H, Go RCP, Harrell LE, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997; 48:139-147.
26. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al., ApoE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 1997; 278:1349-1356. This meta-analysis of ApoE genotype data from 40 research groups clearly examines the ApoE-4 effect by age, sex, and ethnicity. This study is a model for future pooled analyses of candidate gene data.
27. Corder EH, Saunders AM, Risch N, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Apolipoprotein E type 2 allele decreases the risk of late onset Alzheimer disease. Nature Genet 1994; 7:180-184.
28. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Apolipoprotein E-a2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997; 48:515-519.
29. Sorbi S, Nacmias B, Forleo P, Latorraca S, Gobbini I, Bracco L, et al. ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 1994; 177:100-102.
30. van Duijn CM, de Knijff P, Wehnert A, De Voecht J, Bronzova JB, Havekes LM, et al. The apolipoprotein E e2 Allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995; 37:605-610.
31. Scott WK, Saunders AM, Gaskell PC, Locke PA, Growdon JH, Farrer LA, et al. Apolipoprotein E a2 does not increase risk of early-onset sporadic Alzheimer disease. Ann Neurol 1997; 42:376-378.
32. Katzman R, Zhang M-Y, Chen PJ, Gu N, Jiang S, Saitoh T, et al. Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of Dementia. Neurology 1997; 49:779-785. This population-based incidence study of Alzheimer's disease in China reported ApoE-4-associated risks similar to those obtained in clinic-based studies.
33. •].
34. Sahota A, Yang M, Gao S, Hui SL, Baiyewu O, Gureje O, et al. Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Ann Neurol 1997; 42:659-661.
35. Maestre G, Ottman R, Stem Y, Gurland B, Chun M, Tang MX, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995; 37:254-259.
36. Tang MX, Maestre G, Tsai WY, Liu XH, Feng L, Chung WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on ApoE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet 1996; 58:574-584.
37. Corder EH, Saunders AM, Strittmatter WJ, Schmechel D, Gaskell PC, Rimmler JB, et al. Apolipoprotein E, survival in Alzheimer disease patients and the competing risks of death and Alzheimer disease. Neurology 1995; 45:1323-1328.
38. Bickeboller H, Campion D, Brice A, Amouyel P, Hannequin D, Didierjean O, et al. Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet 1997; 60:439-446. This paper examines the effect of ApoE-4 by age and sex in a large (417 cases: 1030 control individuals) case-control study. No differences in the ApoE-4 effect were found in men and women, but the effect of ApoE-4 was estimated to have its strongest effect between the ages of 60 and 79 years.
39. Payami H, Montee KR, Kaye JA, Bird TD, Yu C-E, Schellenberg GD. Alzheimer's disease, apolipoprotein E4, and gender. JAMA 1994; 271:1316-1317.
40. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu C-E, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1996; 58:803-811.
41. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Roses AD, et al. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. JAMA 1995; 273:373-374.
42. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, et al. Synergistic effects of traumatic head injury and apolipoprotein epsilon4 in patients with Alzheimer's disease. Neurology 1995; 45:555-557.
43. O'Meara ES, Kukull WA, Sheppard L, Bowen JD, McCormick WC, Teri L, et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol 1997; 146:373-384.
44. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC. van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997; 349:151-154.
45. Kalaria RN. Arteriosclerosis, apolipoprotein E, and Alzheimer's disease. Lancet 1997; 349:1174.
46. Murphy GM, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR. No association between apolipoprotein E a4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry 1997; 154:603-608.
47. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996; 47:444-448.
48. Dal Forno G, Rasmusson X, Brandt J, Carson KA, Brookmeyer R, Troncosco J, Kawas CH. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996; 53:345-350.
49. Stem Y, Brandt J, Albert M, Jacobs DM, Liu X, Bell K, et al. The absence for an apolipoprotein a4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41:615-620.
50. Caffarra P, Durante D, Calabrese E, Pizzuti A, Farina E, Copelli S, Mariani C. ApoE genotype and cognitive functions in Alzheimer's disease. Alzheimer's Res 1996; 2:185-188.
51. Spielman RS, Ewens WJ. A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. Am J Hum Genet 1998; 62:450-458. This recent publication extends the authors' transmission/disequilibrium test for candidate gene analysis to pairs of affected and unaffected siblings. This extension allows a transmission/disequilibrium test-style candidate gene analysis in late-onset diseases (such as Alzheimer's disease), in which parents are unavailable for genotyping.
52. Curtis D. Use of siblings as controls in case-control association studies. Ann Hum Genet 1997; 61:319-333.
53. Boehnke M, Langefeld CD. Genetic association mapping based on discordant sib pairs: the discordant alleles test (DAT). Am J Hum Genet 1998; (in press).
54. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nature Genet 1995; 10:486-488.
55. 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E a4 carriers. Ann Neurol 1997; 42:115-117.
56. Talbot C, Houlden H, Craddock N, Crook R, Hutton M, Lendon C, et al. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. NeuroReport 1996; 7:534-536.
57. 1-antichymotrypsin type A allele in Alzheimer's disease. NeuroReport 1997; 8:2639-2643.
58. Morgan K, Morgan L, Carpenter K, Lowe J, Lam L, Cave S, et al. Microsatellite polymorphism of the alpha 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Hum Genet 1997; 99:27-31.
59. Wragg M, Hutton M, Talbot C, Alzheimer's Disease Collaborative Group. Genetic association between an intronic polymorphism in the presenilin 1 gene and late onset Alzheimer's disease. Lancet 1996; 347:509-512.
60. Kehoe P, Williams J, Holmans P, Liddell M, Lovestone S, Holmes C, et al. Association between a PS-1 intronic polymorphism and late onset Alzheimer's disease. NeuroReport 1996; 7:2155-2158.
61. Isoe K, Urakami K, Ji Y, Adachi Y, Nakashima K. Presenilin-1 polymorphism in patients with Alzheimer's disease, vascular dementia, and alcohol-associated dementia in Japanese population. Acta Neurol Scand 1996; 94:326-328.
62. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, et al. Genetic association of very low density lipoprotein (VLDL) receptor gene locus with sporadic Alzheimer's disease. Nature Genet 1995; 11:207-209.
63. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett 1997; 222:187-190.
64. Wavrant-DeVrieze F, Perez-Tur J, Lambert JC, Frigard B, Pasquier F, Delacourte A, et al. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett 1997; 227:68-70.
65. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997; 49:56-61.
66. Curran M, Middleton D, Edwardson J, Perry R, McKeith I, Morris C, Neill D. HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease. NeuroReport 1997; 8:1467-1469.
67. Payami H, Schellenberg GD, Zareparsi S, Kaye J, Sexton GJ, Head MA, et al. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 1997; 49:512-518.
68. Nakano K, Ohta S, Nishimaki K, Miki T, Matuda S. Alzheimer's disease and DLST genotype. Lancet 1997; 350:1367-1368.
69. Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, et al. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. NeuroReport 1997; 8:683-686.
70. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Molec Genet 1997; 6:1933-1936.
71. Chagnon P, Robitaille Y, Gauvreau D. Brain mitochondrial DNA polymorphism and cytochrome oxidase activity in Alzheimer's disease. Alzheimer's Res 1996; 2:237-242.
72. Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, et al. No genetic effect of α1-antichymotrypsin in Alzheimer disease. Genomics 1996; 33:53-56.
73. 1-antichymotrypsin and apolipoprotein E polymorphism in very old adults age 75+. Alzheimer's Res 1996; 2:51-54.
74. Müller U, Bödeker R-H, Gerundt I, Kurz A. Lack of association between α1-antichymotrypsin polymorphism, Alzheimer's disease, and allelle a4 of apolipoprotein E. Neurology 1996; 47:1575-1577.
75. 1-antichymotrypsin polymorphism in Alzheimer's disease. Ann Neurol 1996; 40:678-680.
76. Christie J, Lamb H, Singleton AB, Leake A, Melton LM, Perry RH, et al. Determination of the alpha-1 anti-chymotrypsin polymorphism in Alzheimer's disease. Alzheimer's Res 1996; 2:201-204.
77. 1-antichymotrypsin and apolipoprotein E gene polymorphisms in the risk of Alzheimer's disease. Alzheimer's Res 1996; 2:149-152.
78. Fallin D, Reading S, Schinka J, Hoyne J, Scibelli P, Gold M, et al. No interaction between the APOE and alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am J Med Genet 1997; 74:192-194.
79. Didierjean O, Martinez M, Campion D, Hannequin D, Dubois B, Martin C, et al. No effect of the α1-antichymotrypsin A allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997; 63:103-105.
80. Murphy GM, Sullivan EV, Gallagher-Thompson D, Thompson LW, van Duijn CM, Forno LS, et al. No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease. Neurology 1997; 48:1313-1316.
81. Scott WK, Yamaoka LH, Locke PA, Rosi BL, Gaskell PC, Saunders AM, et al. No association or linkage between an intronic polymorphism of Presnilin-1 and sporadic or late-onset familial Alzheimer disease. Genet Epidemiol 1997; 14:307-315.
82. Cai X, Stanton J, Fallin D, Hoyne J, Duara R, Gold M, et al. No association between the intronic presenilin-1 polymorphism and Alzheimer's disease in clinic and population-based samples. Am J Med Genet 1997; 74:202-203.
83. Korovaitseva GI, Bukina A, Farrer LA, Rogaev EI. Presenilin polymorphisms in Alzheimer's disease. Lancet 1997; 350:959.
84. Pritchard ML, Saunders AM, Gaskell PC, Small GW, Conneally PM, Rosi BL, et al. No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer disease in American Caucasians. Neurosci Lett 1996; 209:105-108.
85. Arinami T, Takekoshi K, Yanagi H, Hamamoto M, Hamaguchi H. The 5-repeat allele in the very-low-density lipoprotein receptor gene polymorphism is not increased in sporadic Alzheimer's disease in Japanese. Neurology 1996; 47:1349-1350.
86. Fallin D, Gauntlett AC, Scibelli P, Cai X, Duara R, Gold M, et al. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol 1997; 14:299-305.
87. Clatworthy AE, Gomez-Isla T, Rebeck GW, Wallace RB, Hyman BT. Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. Arch Neurol 1997; 54:1289-1292.
88. Fallin D, Kundtz A, Town T, Gauntlett AC, Duara R, Barker W, et al. No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. Neurosci Lett 1997; 233:145-147.
89. Scott WK, Yamaoka LH, Bass MP, Gaskell PC, Conneally PM, Small GW, et al. No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease. Neurogenetics 1998; 1:179-183.
90. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, et al. Complete genomic screen in late-onset familial Alzheimer disease: evidence for a new locus on chromosome 12. JAMA 1997; 278:1237-1241. This report of a recently completed genomic screen in 54 late-onset Alzheimer's disease families identifies a region on chromosome 12 that is likely to harbor an additional Alzheimer's disease susceptibility gene.
91. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to Tacrine therapy. Ann N Y Acad Sci 1996; 802:101-110.
92. Richard F, Helbecque N, Neuman E, Guez D, Levy R, Amouyel P. APOE genotyping and response to drug treatment in Alzheimer's disease (letter). Lancet 1997; 349:539.
93. Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA 1997; 277:832-836. This most recent consensus statement on genetic testing considers testing for mutations in APP, presenilin-1 and presenilin-2 responsible for autosomal dominant, early-onset Alzheimer's disease, as well as predictive and diagnostic use of APOE genotyping in late-onset.
94. Saunders AM, Hulette C, Welsh-Bohmer KA, Schmechel DE, Crain B, Burke JR, et al. Specificity, sensitivity, and predictive value of apolipoprotein E genotyping for sporadic Alzheimer's disease. Lancet 1996; 348:90-93.
95. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, Mirra S. Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Ann Neurol 1997; 42:319-325. This neuropathologic study from the Consortium to Establish a Registry for Alzheimer's Disease confirmed the results from other studies [94,96,97], reporting specificity and sensitivity of 83% and a positive predictive value of 97% for the use of the ApoE-4 allele as a test for Alzheimer's disease in patients with a probable diagnosis.
96. Kakulas BA, Wilton SD, Fabian VA, Jones TM. Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease (letter). Lancet 1996; 348:483.
97. Smith AD, Jobst KA, Johnston C, Joachim C, Nagy Z. Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet 1996; 348:483-484.
98. Roses AD. Genetic testing for Alzheimer's disease: practical and ethical issues. Arch Neurol 1997; 54:1226-1229. Given the eventual discovery of a second susceptibility locus, this commentary discusses the need for developing ethical guidelines for genetic testing in late-onset Alzheimer's disease.
99. Frisoni GB, Trabucchi M. Clinical rationale of genetic testing in dementia. J Neurol Neurosurg Psychiatry 1997; 62:217-221. This editorial discusses clinical reasons for genetic testing in both autosomal dominant, early-onset Alzheimer's disease and late-onset Alzheimer's disease.
100. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996; 347:1091-1095.
101. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995; 274:1627-1629.